Methods and compositions for treatment of macular and retinal disease
View Patent ↗The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
1. A compound for the treatment of an eye disorder in a patient comprising a therapeutic agent chemically linked to a carotenoid, wherein said therapeutic agent is an anti-angiogenic compound selected from the group consisting of anecortave acetate, pegaptanib (EYE001), Rhu-fab and a protein kinase C inhibitor according to the chemical structure:
and wherein the carotenoid acts as a carrier to facilitate uptake of the therapeutic agent in the retina and or the macula.
2. The compound of claim 1 , wherein the carotenoid comprises a xanthophyll.
3. The compound of claim 2 , wherein the xanthophyll comprises zeaxanthin.
4. The compound of claim 1 , wherein the linkage between the therapeutic agent and the carotenoid comprises a biologically cleavable bond.
5. The compound of claim 1 , wherein a spacer molecule is used to link the therapeutic agent to the carotenoid.
6. The compound of claim 1 , wherein the linkage between the therapeutic agent and the carotenoid comprises an amino acid spacer, a carbonate spacer, an ester bond, an amide bond, or a dicarboxylic acid bond.
7. The compound of claim 1 wherein said therapeutic agent is anecortave acetate.
8. The compound of claim 1 wherein said therapeutic agent is pegaptanib.
9. The compound of claim 1 wherein said therapeutic agent is Rhu-fab.
10. The compound of claim 1 wherein said therapeutic agent is a said protein kinase C inhibitor.
11. A composition for the treatment of an eye disorder in a patient comprising a pharmaceutically effective amount of a prodrug comprising a therapeutic agent linked to a carotenoid, wherein said therapeutic agent is an anti-angiogenic compound selected from the group consisting of anecortave acetate, pegaptanib (EYE001), Rhu-fab and a protein kinase C inhibitor compound according to the chemical structure:
and a pharmaceutically acceptable carrier, wherein a pharmaceutically effective amount of the prodrug comprises an amount sufficient to ameliorate the eye disorder.
12. The composition of claim 11 , wherein the carotenoid comprises a xanthophyll.
13. The composition of claim 11 wherein said therapeutic agent is anecortave acetate.
14. The composition of claim 11 wherein said therapeutic agent is pegaptanib.
15. The composition of claim 11 wherein said therapeutic agent is Rhu-fab.
16. The composition of claim 11 wherein said therapeutic agent is said protein kinase C inhibitor.
17. A kit for the treatment of an eye disorder in a patient comprising:
(a) a prodrug compound comprising a therapeutic agent linked to a carotenoid wherein said therapeutic agent is an anti-angiogenic agent selected from the group consisting of anecortave acetate, pegaptanib (EYE001), Rhu-fab and a protein kinase C inhibitor according to the chemical structure:
(b) a pharmaceutically acceptable carrier; and
(c) instructions to dispense a pharmaceutically effective amount of the prodrug in the pharmaceutically acceptable carrier to an individual in need thereof, wherein a pharmaceutically effective amount of the prodrug comprises an amount of sufficient to ameliorate an eye disorder in the individual.
18. The kit of claim 17 , wherein the carotenoid comprises a xanthophyll.
19. The kit of claim 17 wherein said therapeutic agent is anecortave acetate.
20. The kit of claim 17 wherein said therapeutic agent is pegaptanib.
21. The kit of claim 17 wherein said therapeutic agent is Rhu-fab.
22. The kit of claim 17 wherein said therapeutic agent is said protein kinase C inhibitor.